| Tên sản phẩm | Mavacamten |
| Tên khác | MYK-461 |
| Số CAS | 1642288-47-8 |
| Công thức phân tử | C₁₅H₁₉N₃O₂ |
| Trọng lượng phân tử | 273.33 g/mol |
| Hình thức | Bột tinh thể màu trắng đến trắng ngà |
| Độ tinh khiết (HPLC) | ≥ 99,01 TP3T |
| Mất mát khi sấy khô | ≤ 0,5% |
| Kim loại nặng | ≤ 10 ppm |
Cần trợ giúp? Liên hệ với đội ngũ của chúng tôi
Mavacamten (development code MYK-461) is a first-in-class, selective, allosteric inhibitor of cardiac myosin. It is the first pharmacological agent approved to target the underlying pathophysiology of hypertrophic cardiomyopathy (HCM) —a condition characterized by excessive cardiac muscle contraction, hypercontractility, and impaired relaxation (diastolic dysfunction).
Mechanism of action: Mavacamten binds selectively to the catalytic domain of cardiac myosin ATPase, reducing the number of myosin heads available for actin binding. This decreases cardiac contractility, reduces left ventricular outflow tract (LVOT) gradient, and improves diastolic filling.
Chemical structure highlights:
Small molecule (MW 273.33)
Allosteric modulator (not ATP-competitive)
Highly selective for cardiac myosin (vs. smooth muscle or skeletal myosin)
Oral bioavailability (well-absorbed)
Synonym：MYK-461(SAR-439152);SAR439152;SAR439152;SAR-439152;SAR-439152;SAR439152;SAR439152;MYK-461;MYK461;MYK461;MAVACAMTEN;MYK-461-Mavacamten|SAR439152;Mavacamten(MYK-461;2,4(1H,3H)-Pyrimidinedione,3-(1-methylethyl)-6-[[(1S)-1-phenylethyl]amino]-
280 Phố Chính, Tây An, Thiểm Tây, Trung Quốc
English English 
Russian
French
Korean
German
Polish
Japanese
Spanish
Italian
Vietnamese